Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Phase 1 · ActiveModality: cell therapy (off-the-shelf iPSC-derived CAR T-cell)
Target CD19
Partnerships $7.9M CIRM award (Feb 2024) supporting the Phase 1 study in SLE (award period Apr 2024-Mar 2028).
Indications
Systemic lupus erythematosus (moderate-to-severe), with and without lupus nephritis(Phase 1)
Systemic sclerosis (SSc)(Phase 1)
ANCA-associated vasculitis (AAV)(Phase 1)
Idiopathic inflammatory myositis (IIM)(Phase 1)
Status note Off-the-shelf, iPSC-derived, CD19-targeted CAR T-cell product candidate designed to deplete disease-causing B cells in B cell-mediated autoimmune diseases. Multi-center Phase 1 in moderate-to-severe SLE (U.S., U.K., EU); dose-escalation at 900M cells completed in SLE, dose-expansion cohorts initiated in SSc, AAV and IIM (first SSc patient treated Oct 2025). FDA Regenerative Medicine Advanced Therapy (RMAT) designation for moderate-to-severe SLE (Apr 2025); company plans a Phase 2 registration-enabling protocol in lupus nephritis then extrarenal lupus, advancing toward BLA over the next several years.
FT522
Stage not disclosed · ActiveModality: cell therapy (off-the-shelf iPSC-derived CAR NK cell)
Target CD19
Indications
B cell-mediated autoimmune diseases(Stage not disclosed)
Status note Off-the-shelf, CD19-targeted CAR NK cell candidate incorporating high-affinity non-cleavable CD16 (hnCD16) Fc receptor and Alloimmune Defense Receptor (ADR) technology designed to reduce the need for intense conditioning chemotherapy. FDA IND allowed Oct 2024 for B cell-mediated autoimmune diseases; company evaluating opportunities and timelines for clinical development, including potential combination with CD20/CD38 antibodies without conditioning chemotherapy.
Partnerships In clinical collaboration with Ono Pharmaceutical (R&D collaboration for off-the-shelf multiplexed-engineered iPSC-derived CAR T/NK candidates for solid tumors).
Indications
Solid tumors(Phase 1)
Status note First multiplexed-engineered CAR T-cell candidate for solid tumors, incorporating seven novel synthetic controls including a cancer-selective HER2 binding domain (preferentially recognizes tumor-associated HER2 variants), synthetic CXCR2 receptor for tumor trafficking, synthetic TGFβ receptor to resist immunosuppression, and hnCD16. Phase 1 investigation ongoing.
FT836
Preclinical · ActiveModality: cell therapy (off-the-shelf iPSC-derived CAR T-cell)
Target MICA/MICB
Partnerships $4.0M CIRM award (Jan 2025) supporting preclinical and IND-enabling activities (award period May-Oct 2025).
Indications
Cancer (pan-tumor strategy)(Stage not disclosed)
Status note Off-the-shelf CAR T-cell candidate targeting MICA/MICB stress proteins via a shedding-resistant domain as a pan-tumor strategy; incorporates 9 edits including hnCD16 for ADCC and Sword & Shield/ADR technology designed to reduce the need for conditioning chemotherapy.
FT839
Preclinical · ActiveModality: cell therapy (off-the-shelf iPSC-derived CAR T-cell)
Target CD19 / CD38
Indications
Autoimmune diseases and hematological malignancies(Stage not disclosed)
Status note Next-generation CAR T program expressing two distinct CARs targeting CD19 and CD38, incorporating 13 edits including CD3 Fusion Receptor, hnCD16, and Sword & Shield technology. Described as a preclinical program; no clinical trial disclosed in the excerpts.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (6 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.